Back HIV Treatment Treatment Guidelines

HIV Treatment Guidelines

HIV11: New Studies Challenge Evidence of Reduced Abacavir Potency When Viral Load Is High

An analysis of 2 studies of the new HIV integrase inhibitor dolutegravir presented at the 11th International Congress on Drug Therapy in HIV Infection this month in Glasgow had the incidental effect of bringing into question evidence from a previous study suggesting that the nucleoside reverse transcriptase inhibitor abacavir (Ziagen, also in the Epzicom or Kivexa coformulation) was less potent in people starting HIV therapy with high viral loads than another NRTI drug, tenofovir (Viread, also in the Truvada, Atripla, Complera, and Stribild coformulations). alt

Read more:

HHS Updates Antiretroviral Treatment Guidelines for Children with HIV

On November 1, 2012, the U.S. Department of Health and Human Services (HHS) released the latest revision of its Guidelines for the Use of Antiretroviral Agents in Pediatric HIV Infection. Key changes include new information on HIV diagnosis of children, when to start treatment, and discussion of newer antiretroviral drugs. alt

Read more:

New Guidelines: Antiretroviral Therapy and Optimized Care for People with HIV

The U.S. Department of Health and Human Services this week released updated Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents. DHHS panel member Paul Dalton provides a summary of the changes.

Earlier this month the International Association of Physicians in AIDS Care (IAPAC) released guidelines for improving entry into and retention in care for people with HIV, as well as optimizing adherence to antiretroviral therapy.alt

Read more:

New Guidance Addresses Expanded Antiretroviral Treatment, Perinatal ART, PrEP

On the occasion of the XIX International AIDS Conference (AIDS 2012) last week in Washington, DC, the International Antiviral Society-USA (IAS-USA) released new guidelines recommending that all people diagnosed with HIV should be offered antiretroviral therapy (ART).alt

Read more:

CROI 2012: San Francisco Early HIV Treatment Policy Linked to Lower Viral Load, Higher CD4 Count

San Francisco's policy of offering antiretroviral therapy (ART) to everyone who tests positive for HIV regardless of CD4 T-cell count has resulted in higher average CD4 counts at the time of treatment initiation and faster suppression of HIV viral load, researchers reported at the at the 19th Conference on Retroviruses and Opportunistic Infections (CROI 2012) this month in Seattle.alt

Read more: